SOX11 as a prognostic biomarker linked to m6A modification and immune infiltration in renal clear cell carcinoma.

IF 1.5 4区医学 Q4 ONCOLOGY

Translational cancer research Pub Date : 2024-07-31 Epub Date: 2024-07-15 DOI:10.21037/tcr-24-109

Kaihong Wang, Xinpeng Chen, Yifu Liu, Xuan Meng, Libo Zhou

{"title":"SOX11 as a prognostic biomarker linked to m6A modification and immune infiltration in renal clear cell carcinoma.","authors":"Kaihong Wang, Xinpeng Chen, Yifu Liu, Xuan Meng, Libo Zhou","doi":"10.21037/tcr-24-109","DOIUrl":null,"url":null,"abstract":"Background: The prognosis for patients with kidney renal clear cell carcinoma (KIRC) remains unfavorable, and the understanding of SRY-box transcription factor 11 (SOX11) in KIRC is still limited. The purpose of this paper is to explore the role of SOX11 in the prognosis of KIRC.Methods: We analyzed SOX11 expression in KIRC and adjacent normal tissues using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Our study aims to establish a correlation between SOX11 expression and clinical pathological features. Differentially expressed genes (DEGs) were assessed using R software. Furthermore, we conducted Gene Ontology (GO)/Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses and gene set enrichment analysis (GSEA). Integration of data from the Tumor Immune Estimation Resource (TIMER) and TCGA databases allowed us to assess the association between SOX11 expression and immune infiltration in KIRC. Additionally, we analyzed the association between SOX11 gene expression and N6-methyladenosine (m6A) modification in KIRC using TCGA and GEO data.Results: Our findings revealed high SOX11 expression in KIRC, which showed a significant correlation with tumor staging and prognosis. GO/KEGG and GSEA analyses indicated that SOX11 was closely associated with sodium ion transport, synaptic vesicle circulation, and oxidative phosphorylation. Analysis of the TIMER and TCGA databases demonstrated correlations of SOX11 expression levels with the presence of CD8+ T lymphocytes, neutrophils, CD4+ T cells, as well as B cells. Moreover, both the TCGA and GEO datasets showed a substantial association between SOX11 and m6A modification-related genes, namely ZC3H13, FTO, METTL14, YTHDC1, IGF2BP1, and IGF2BP2.Conclusions: SOX11 exhibits a correlation with m6A modification and immune infiltration, suggesting its potential as a prognostic biomarker for KIRC.","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11319951/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-24-109","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/15 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The prognosis for patients with kidney renal clear cell carcinoma (KIRC) remains unfavorable, and the understanding of SRY-box transcription factor 11 (SOX11) in KIRC is still limited. The purpose of this paper is to explore the role of SOX11 in the prognosis of KIRC.

Methods: We analyzed SOX11 expression in KIRC and adjacent normal tissues using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Our study aims to establish a correlation between SOX11 expression and clinical pathological features. Differentially expressed genes (DEGs) were assessed using R software. Furthermore, we conducted Gene Ontology (GO)/Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses and gene set enrichment analysis (GSEA). Integration of data from the Tumor Immune Estimation Resource (TIMER) and TCGA databases allowed us to assess the association between SOX11 expression and immune infiltration in KIRC. Additionally, we analyzed the association between SOX11 gene expression and N6-methyladenosine (m6A) modification in KIRC using TCGA and GEO data.

Results: Our findings revealed high SOX11 expression in KIRC, which showed a significant correlation with tumor staging and prognosis. GO/KEGG and GSEA analyses indicated that SOX11 was closely associated with sodium ion transport, synaptic vesicle circulation, and oxidative phosphorylation. Analysis of the TIMER and TCGA databases demonstrated correlations of SOX11 expression levels with the presence of CD8⁺ T lymphocytes, neutrophils, CD4⁺ T cells, as well as B cells. Moreover, both the TCGA and GEO datasets showed a substantial association between SOX11 and m6A modification-related genes, namely ZC3H13, FTO, METTL14, YTHDC1, IGF2BP1, and IGF2BP2.

Conclusions: SOX11 exhibits a correlation with m6A modification and immune infiltration, suggesting its potential as a prognostic biomarker for KIRC.

查看原文本刊更多论文

SOX11 作为预后生物标志物与肾透明细胞癌的 m6A 修饰和免疫浸润有关。

背景：肾透明细胞癌（KIRC）患者的预后仍然不容乐观，而人们对SRY-盒转录因子11（SOX11）在KIRC中的作用的了解仍然有限。本文旨在探讨SOX11在KIRC预后中的作用：我们利用癌症基因组图谱（TCGA）和基因表达总库（GEO）数据库分析了SOX11在KIRC和邻近正常组织中的表达。我们的研究旨在建立SOX11表达与临床病理特征之间的相关性。我们使用 R 软件评估了差异表达基因（DEGs）。此外，我们还进行了基因本体（GO）/京都基因组百科全书（KEGG）分析和基因组富集分析（GSEA）。通过整合肿瘤免疫估算资源（TIMER）和TCGA数据库的数据，我们评估了SOX11的表达与KIRC中免疫浸润之间的关联。此外，我们还利用TCGA和GEO数据分析了KIRC中SOX11基因表达与N6-甲基腺苷（m6A）修饰之间的关联：我们的研究结果表明，SOX11在KIRC中的高表达与肿瘤分期和预后有显著相关性。GO/KEGG和GSEA分析表明，SOX11与钠离子转运、突触小泡循环和氧化磷酸化密切相关。对 TIMER 和 TCGA 数据库的分析表明，SOX11 的表达水平与 CD8+ T 淋巴细胞、中性粒细胞、CD4+ T 细胞以及 B 细胞的存在相关。此外，TCGA和GEO数据集都显示SOX11与m6A修饰相关基因（即ZC3H13、FTO、METTL14、YTHDC1、IGF2BP1和IGF2BP2）之间存在实质性关联：结论：SOX11与m6A修饰和免疫浸润相关，表明其有可能成为KIRC的预后生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational cancer research ONCOLOGY-

CiteScore

2.10

自引率

0.00%

发文量

252

期刊介绍： Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.